Description: Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by several prognostic factors, a better outcome individualization in a given patient is still of utmost interest. Here, we showed that miR-29c and miR-223 expression levels decreased significantly with progression from Binet Stage A to C, were significantly lower in poor prognostic subgroups (defined by several prognostic factors) and could significantly predict treatment-free survival (TFS) and overall survival (OS). Furthermore, we developed a quantitative real-time PCR score combining miR-29c, miR-223, ZAP70 and LPL (from 0 to 4 poor prognostic markers) to stratify treatment and death risk in a cohort of 110 patients with a median follow-up of 72 months (range, 2-312). Patients with a score of 0/4, 1/4, 2/4, 3/4, and 4/4 had a median TFS of >312, 129, 80, 36 and 19 months, respectively (hazard ratio, HR0/4<1/4<2/4<3/4<4/4=17.00, P<0.0001). Patients with a score of 0-1/4, 2-3/4 and 4/4 had a median OS of >312, 183 and 106 months, respectively (HR0/4<1/4<2/4<3/4<4/4=13.69, P=0.0001). This score will help to identify, among the good and poor prognosis subgroups, patients who will need early therapy and thus will require a closer follow-up.
|
Reference:
MicroRNA-29c and microRNA-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. | PMID:19144983
Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L.
Blood. 2009 Jan 14. [Epub ahead of print] |
